Reported Earlier, HUTCHMED To Present Sovleplenib Phase III ESLIM-01 Study And Hematological Malignancy Programs Data At The Upcoming EHA2024 Congress
Reported Earlier, HUTCHMED To Present Sovleplenib Phase III ESLIM-01 Study And Hematological Malignancy Programs Data At The Upcoming EHA2024 Congress
早些時候報道，和黃醫藥將在即將舉行的 EHA2024 大會上公佈Sovleplenib 三期 ESLIM-01 研究和血液惡性腫瘤項目數據
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association ("EHA") Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
和黃醫藥（中國）有限公司（“和黃醫藥”）（納斯達克/AIM: HCM；HKEX: 13）今天宣佈，sovleplenib ESLIM-01 III期研究的主要和亞組結果，以及與新型研究性血液惡性腫瘤療法 HMPL-306、HMPL-760 和塔澤美司他相關的最新和更新數據，將在即將舉行的歐洲血液學協會（“EHA” Hybrid）上公佈大會，將於2024年6月13日至16日在西班牙馬德里在線舉行。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。